Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
October 04 2022 - 12:01AM
Real Endpoints, the leading market-access platform and advisory
firm, announced a collaboration with bluebird bio, inc. (Nasdaq:
BLUE), to provide multiple health plans with access to an
innovative, outcomes-based agreement for ZYNTEGLO® (betibeglogene
autotemcel) through the Real Endpoints (RE) Marketplace.
These plans cover nearly 16 million individuals across the U.S.;
while treatment-dependent beta-thalassemia is a rare disease,
together these plans comprise a significant portion of the patient
population in the U.S. ZYNTEGLO is currently the only FDA-approved
gene therapy for people with beta-thalassemia who require regular
red blood cell transfusions.
Through a single contract, the plans in RE Marketplace can take
immediate advantage of bluebird’s innovative agreement, which
offers rebates of up to 80% if treatment with ZYNTEGLO does not
enable a patient to achieve and maintain transfusion independence
in the two years following therapy.
RE Marketplace performs all the required analytics and financial
reconciliation as an expert, independent third-party. RE
Marketplace provides participating plans and manufacturers with
end-to-end capabilities for efficient, scalable value-based
contracting – and does so with complete financial and data
transparency.
“bluebird’s ZYNTEGLO is a giant step forward for medicine,”
commented Jane Barlow, MD, Chief Clinical Officer at Real
Endpoints. “The plans in RE Marketplace are thrilled to be able to
easily access bluebird’s innovative risk-sharing agreement, which
speeds the delivery of both clinical and economic innovations. That
is a win for both patients and the broader health system,” she
said.
About RE Marketplace
The RE Marketplace platform provides members of mid-sized and
smaller health plans speedier access to innovative treatments such
as rare disease drugs, cell and gene therapies, and digital
medicines. From four founding member plans, RE Marketplace now
represents several mid-sized and regional plans approaching nearly
16 million beneficiaries across all lines of business. Both
industry and payer participants benefit from the efficiency and
flexibility of RE Marketplace, which can support a range of
innovative contracts through a standard contracting process. There
is also the potential for more generous rebate opportunities
without additional Medicaid Best Price risk. RE Marketplace
performs all the critical analytics and financial reconciliation –
transparently and with full audit rights, using a highly robust,
secure, HIPAA-compliant system already tested and used in multiple
value-based agreements. For more about RE Marketplace, please visit
this link: https://realendpoints.com/products/re-marketplace/
About Real Endpoints
Real Endpoints’ solutions create patient access to meaningful
medical innovations and prepare companies for competition in the
value-based economy. Working collaboratively with biopharma,
diagnostic and medical device companies, RE provides unique answers
across a wide range of coverage and reimbursement issues – from
pricing and distribution to patient support services. RE is also
the leading advisor to the industry on innovative contracting,
including the evaluation, structuring, negotiating, and third-party
management of the analytics and financial reconciliation of
value-based contracts. For more information about Real Endpoints,
visit www.realendpoints.com.
Website:
www.realendpoints.comLinkedIn:
https://www.linkedin.com/company/real-endpoints/
Contact: Aurore Duboille Email:
aduboille@realendpoints.comPhone:
973-805-2300
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024